Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster

Research output: Contribution to journalArticlepeer-review

6 Downloads (Pure)


Studies about the duration of the humoral and cellular response following the bivalent booster administration are still scarce. We aimed at assessing the humoral and cellular response in a cohort of healthcare workers that received this booster. Blood samples were collected before the administration of the bivalent booster from Pfizer-BioNTech and after 14, 28, 90, and 180 days. Neutralizing antibodies against either the D614G strain, the delta variant, the BA.5 variant, or the XBB.1.5 subvariant were measured. The cellular response was assessed by measurement of the release of interferon gamma from T cells in response to an in vitro SARS-CoV-2 stimulation. A substantial waning of neutralizing antibodies was observed after 6 months (23.1-fold decrease), especially considering the XBB.1.5 subvariant. The estimated T 1/2 of neutralizing antibodies was 16.1 days (95% CI = 10.2-38.4 days). Although most participants still present a robust cellular response after 6 months (i.e., 95%), a significant decrease was also observed compared to the peak response (0.95 vs. 0.41 UI/L, p = 0.0083). A significant waning of the humoral and cellular response was observed after 6 months. These data can also help competent national authorities in their recommendation regarding the administration of an additional booster.

Original languageEnglish
Article number10.1002/jmv.29365
Pages (from-to)e29365
JournalJournal of medical virology
Issue number1
Publication statusPublished - Jan 2024


  • Humans
  • BNT162 Vaccine
  • Immunity, Cellular
  • Antibodies, Neutralizing
  • Complementary Therapies
  • Health Personnel


Dive into the research topics of 'Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster'. Together they form a unique fingerprint.

Cite this